Ocular Therapeutix

The glaucoma market in seven major markets (US, France, Germany, Italy, Spain, UK, Japan) is projected to grow from $2.1 billion in 2023 to $2.5 billion by 2033, driven by an aging population and new pipeline products. Key developments include Nicox’s NCX 470 and Ocular Therapeutix’s OTX-TIC, aiming to improve patient compliance and treatment efficacy. Despite a well-established market, challenges like patient compliance and the need for enhanced IOP-lowering therapies persist.

In 2024, pharma saw breakthroughs like Amtagvi for solid tumors and Cobenfy for schizophrenia. Challenges include the Inflation Reduction Act's price negotiations and R&D financial pressures. Innovations expected in 2025 include SERDs for breast cancer, bispecific antibodies in immuno-oncology, and the first tri-specific antibody approval. Clinical trials will evolve with external control arms and adaptive designs, while policy shifts may impact rare disease R&D and obesity care coverage.

The glaucoma market in 7MM is forecasted to grow at a 2.1% CAGR from $2.1B in 2023 to $2.5B in 2033, driven by an aging population and new pipeline products. Key products include NCX 470 and OTX-TIC, with a focus on improving patient compliance and IOP-lowering efficacy. The market faces competition from generics and the challenge of patient acceptance for new treatments.

The glaucoma market in the 7MM is projected to grow at a 2.1% CAGR from $2.1B in 2023 to $2.5B in 2033, driven by an aging population and new pipeline products. Key products include NCX 470 and OTX-TIC, with implants addressing compliance issues. Unmet needs include better IOP-lowering drugs and neuroprotective therapies.

The global Clinical Trials Management System (CTMS) market, valued at USD 2.14 billion in 2024, is projected to grow to USD 9.67 billion by 2035, with a CAGR of 14.67%. Growth drivers include healthcare IT advancements, digital trials adoption, and personalized medicine demand. North America leads in revenue share; Asia Pacific grows fastest. Key players include Oracle Health Sciences and Medidata Solutions.

The global Clinical Trials Management System (CTMS) market, valued at USD 2.14 billion in 2024, is projected to reach USD 9.67 billion by 2035, growing at a CAGR of 14.67%. Growth is driven by healthcare IT advancements, digital trials, and personalized medicine demand. North America leads in revenue, while Asia Pacific grows fastest due to clinical trial expansions and investments.

The Age-related Vision Dysfunction Market report by DelveInsight provides insights into treatment trends, epidemiology, and market forecasts from 2020 to 2034. It highlights key companies and therapies, including bevacizumab and Rocklatan, and discusses the prevalence of conditions like AMD, glaucoma, and cataracts in the US, EU4, UK, and Japan.

The Age-related Vision Dysfunction Market report by DelveInsight forecasts trends, treatments, and epidemiology from 2020 to 2034, highlighting key companies and therapies. It covers conditions like AMD, glaucoma, and diabetic retinopathy, emphasizing the need for innovative treatments in aging populations.

The Dry Eye Disease market is projected to grow significantly by 2034, with the US leading in market size. Prevalence increases with age, affecting more females. Key companies like Alcon and Novaliq are developing therapies, including CEQUA and TYRVAYA, targeting tear production and inflammation. Emerging treatments like Reproxalap and Tivanisiran show promise in addressing symptoms and underlying mechanisms of dry eye disease.

Ocular Therapeutix announced over 300 patients enrolled in SOL-1 phase 3 trial for Axpaxli, an axitinib intravitreal implant for wet AMD. Axpaxli aims to provide durable therapy, potentially dosed every 6-9 months, addressing unmet needs in wet AMD treatment.